Inflection Biosciences Announces Publication of Positive Data for IBL-202 in DLBCL.
Dublin, Ireland, July 30, 2020 – Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of cancer,...
Inflection Biosciences Announces Publication of Positive Data for IBL-202 in DLBCL.
Inflection Biosciences Announces Participation at Upcoming Industry Conferences.
Inflection Biosciences Announces Appointment of Shaun McNulty, Ph.D., as Chief Scientific Officer.
Inflection Biosciences Announces Appointment of Murray Yule, M.D., Ph.D., as Chief Medical Officer
Inflection Biosciences to present at BIO CEO & Investor Conference 2020.